We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Biotech Company Will Focus on POC Diagnostics

By HospiMedica staff writers
Posted on 17 Oct 2007
A new biotech company will develop methods for personalized medicine based on new technologies and advanced data analysis. More...


One of the focus areas of the company will be to develop techniques for point-of-care (POC) diagnostics of different diseases. The techniques developed will also be used for monitoring the patient's condition during and after treatment.

"We have promising results for arthritis, where several different studies show consistent results regarding biomarkers that can distinguish healthy subjects from diagnosed patients. The study is based on serum samples and the goal is to establish collaborations and have a POC diagnostic kit for arthritis on the market in a few years,” commented Jon Gabrielsson, CEO of the new company, AcureOmics AB (Umea, Sweden).

Robust and consistent techniques for analysis of metabolites/biomarkers will also be developed. Development work is ongoing for monitoring the physiologic effects of food supplements. The company also aims to use chemometrics to become competent in the "omics” (genomics, proteomics, and metabolomics/metabonomics) field of data analysis and interpretation.


Related Links:
AcureOmics

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.